Herbal inhibitors of SARS-CoV-2 M pro effectively ameliorate acute lung injury in mice.
Xinyi DuLongxin XuYiming MaShuaiyao LuKegong TangXiangyu QiaoJiaqi LiuXiaona WangXiaozhong PengChengyu JiangPublished in: IUBMB life (2022)
Coronavirus disease 2019, a newly emerging serious infectious disease, has spread worldwide. To date, effective drugs against the disease are limited. Traditional Chinese medicine was commonly used in treating COVID-19 patients in China. Here we tried to identify herbal effective lipid compounds from the lipid library of 92 heat-clearing and detoxication Chinese herbs. Through virtual screening, enzymatic activity and inhibition assays, and surface plasmon resonance tests, we identified lipid compounds targeting the main protease (M pro ) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and verified their functions. Here, we found that natural lipid compounds LPC (14:0/0:0) and LPC (16:0/0:0) could target SARS-CoV-2 M pro , recover cell death induced by SARS-CoV-2, and ameliorate acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) induced by bacterial lipopolysaccharides and virus poly (I:C) mimics in vivo and in vitro. Our results suggest that LPC (14:0/0:0) and LPC (16:0/0:0) might be potential pan remedy against ARDS.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- acute respiratory distress syndrome
- extracorporeal membrane oxygenation
- coronavirus disease
- mechanical ventilation
- cell death
- fatty acid
- anti inflammatory
- lipopolysaccharide induced
- infectious diseases
- lps induced
- type diabetes
- metabolic syndrome
- adipose tissue
- cell proliferation
- intensive care unit
- cancer therapy
- climate change
- drug delivery
- high fat diet induced
- signaling pathway
- pi k akt